Ohcanbohtosat - Shebl, Amgad

  • Čájehuvvo 1 - 6 / 6
Aiddostahte ozu
  1. 1
    Anti‐A/B isoagglutinin reduction in an intravenous immunoglobulin product and risk of hemolytic anemia: a hospital‐based cohort study

    Anti‐A/B isoagglutinin reduction in an intravenous immunoglobulin product and risk of hemolytic anemia: a hospital‐based cohort study Dahkki Wallenhorst, Christopher, Patel, Ami, Shebl, Amgad, Hubsch, Alphonse, Simon, Toby L., Martinez, Carlos

    Almmustuhtton 2020
    Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta
    Teaksta
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    Impact of screening and exclusion of high anti‐A titer donors on the risk of hemolytic anemia with intravenous immunoglobulin treatment: A hospital‐based cohort study in the US

    Impact of screening and exclusion of high anti‐A titer donors on the risk of hemolytic anemia with intravenous immunoglobulin treatment: A hospital‐based cohort study in the US Dahkki Martinez, Carlos, Watson, Douglas J., Shebl, Amgad, Wallenhorst, Christopher, Hubsch, Alphonse, Simon, Toby L.

    Almmustuhtton 2017
    Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta
    Teaksta
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    Isoagglutinin reduction in intravenous immunoglobulin (IgPro10, Privigen) by specific immunoaffinity chromatography reduces its reporting rates of hemolytic reactions: an analysis of spontaneous adverse event reports

    Isoagglutinin reduction in intravenous immunoglobulin (IgPro10, Privigen) by specific immunoaffinity chromatography reduces its reporting rates of hemolytic reactions: an analysis... Dahkki Shebl, Amgad, Gabriel, Susie, Van Dinther, Kristy, Hubsch, Alphonse, Lawo, John‐Philip, Hoefferer, Liane, Welsh, Susan

    Almmustuhtton 2020
    Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta
    Teaksta
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    Safety of biweekly α(1)-antitrypsin treatment in the RAPID programme

    Safety of biweekly α(1)-antitrypsin treatment in the RAPID programme Dahkki Greulich, Timm, Chlumsky, Jan, Wencker, Marion, Vit, Oliver, Fries, Michael, Chung, Thomas, Shebl, Amgad, Vogelmeier, Claus, Chapman, Kenneth R., McElvaney, Noel G.

    Almmustuhtton 2018
    Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta
    Teaksta
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study)

    Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA stu... Dahkki Léger, Jean-Marc, De Bleecker, Jan L, Sommer, Claudia, Robberecht, Wim, Saarela, Mika, Kamienowski, Jerzy, Stelmasiak, Zbigniew, Mielke, Orell, Tackenberg, Björn, Shebl, Amgad, Bauhofer, Artur, Zenker, Othmar, Merkies, Ingemar S J

    Almmustuhtton 2013
    Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta
    Teaksta
    Lasit oiddohiidda
    Furkejuvvon:
  6. 6
    Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneuropathy And Treatment with Hizentra study

    Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneur... Dahkki Mielke, Orell, Bril, Vera, Cornblath, David R., Lawo, John‐Philip, van Geloven, Nan, Hartung, Hans‐Peter, Lewis, Richard A., Merkies, Ingemar S.J., Sobue, Gen, Durn, Billie, Shebl, Amgad, van Schaik, Ivo N.

    Almmustuhtton 2019
    Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta
    Teaksta
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: